ClinConnect ClinConnect Logo
Search / Trial NCT06472869

Assessing E-Cigarettes for Tobacco Harm Reduction in the Context of Lung Cancer Screening

Launched by MASSACHUSETTS GENERAL HOSPITAL · Jun 19, 2024

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Tobacco Use Disorder

ClinConnect Summary

This clinical trial is exploring whether giving electronic cigarettes (ECs) to smokers who are not planning to quit can help reduce their tobacco use, especially in the context of lung cancer screening. Over four weeks, 30 participants will receive free NJOY ACE 5% nicotine ECs and will be encouraged to switch from traditional cigarettes to ECs. The study aims to understand how many people are interested in joining, how acceptable the ECs are to them, and whether their smoking habits change, as well as measuring certain substances in their body that indicate tobacco use.

To be eligible, participants must have recently completed another study, smoke at least five cigarettes a day, and be willing to switch to ECs for the trial. They also need to be comfortable attending three in-person visits at Massachusetts General Hospital and own a mobile phone. Throughout the study, participants will be monitored for changes in their cigarette consumption and other health markers. This trial is currently recruiting, and it offers an opportunity for individuals who are not ready to quit smoking to explore a potentially less harmful alternative.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Participants who completed the Screen Assist study (NCT03611881) and self-reported smoking cigarettes at the end of the study were asked to complete a survey to ascertain their potential interest in participating in a research study to test the effects of switching from combustible cigarettes (CC) to electronic cigarettes (EC). Individuals who expressed interest in switching to EC on that survey were screened for eligibility for this pilot study
  • Smoked ≥5 cigarettes/day in past month
  • Smoking status at study entry confirmed by breath carbon monoxide (CO) ≥ 6ppm
  • Willing to try switching from CC to EC for 4 weeks
  • Owns a mobile telephone
  • English speaking
  • Willing to travel to the Massachusetts General Hospital campus for 3 in-person visits.
  • Exclusion Criteria:
  • Plans to quit smoking and has set a quit date in the next 30 days
  • Used smoking cessation treatment in the past 30 days
  • Used EC on \>2 days in the past 30 days
  • Hospitalized for acute coronary syndrome, unstable angina, congestive heart failure, stroke, pneumonia or chronic pulmonary disease/asthma exacerbation in the past 1 month
  • Not willing to abstain from smoking marijuana in the 24h before each study visit

About Massachusetts General Hospital

Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.

Locations

Boston, Massachusetts, United States

Patients applied

0 patients applied

Trial Officials

Nancy A. Rigotti, MD

Principal Investigator

Massachusetts General Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported